Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -1.29M | $ -1.18M | $ -1.05M | $ -217.00K |
| Operating Income | $ -104.03M | $ -75.64M | $ -68.67M | $ -56.65M | $ -57.04M |
| EBITDA | $ -104.03M | $ -74.81M | $ -65.88M | $ -55.97M | $ -56.82M |
| Net Income | $ -102.02M | $ -71.17M | $ -65.45M | $ -56.41M | $ -55.84M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 113.09M | $ 188.59M | $ 127.87M | $ 111.80M | $ 159.90M |
| Total Assets | $ 123.18M | $ 200.85M | $ 139.19M | $ 123.54M | $ 169.36M |
| Total Debt | $ 15.41M | $ 46.59M | $ 6.78M | $ 3.37M | $ 1.29M |
| Net Debt | $ -5.67M | $ 12.00M | $ -26.14M | $ -19.95M | $ -158.61M |
| Total Liabilities | $ 65.36M | $ 60.37M | $ 20.80M | $ 14.27M | $ 11.26M |
| Stockholders' Equity | $ 57.83M | $ 140.48M | $ 118.59M | $ 109.27M | $ 158.10M |
| Cash Flow | |||||
| Free Cash Flow | $ -91.97M | $ -70.97M | $ -58.17M | $ -48.55M | $ -36.54M |
| Operating Cash Flow | $ -91.91M | $ -70.67M | $ -57.76M | $ -48.15M | $ -35.97M |
| Investing Cash Flow | $ 67.00M | $ -53.65M | $ -5.40M | $ 42.80M | $ -117.18M |
| Financing Cash Flow | $ 11.40M | $ 125.97M | $ 72.79M | $ 609.00K | $ 149.81M |